Phase 1 results point to larger trial of enzalutamide and fulvestrant in breast cancer

December 8th, 2015 | Posted by admin in Uncategorized

Results of a multicenter phase 1 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium show that the anti-androgen agent enzalutamide is active and well-tolerated alone and with...
Source: Medical News Today

You can follow any responses to this entry through the RSS 2.0 You can leave a response, or trackback.

Leave a Reply

Your email address will not be published. Required fields are marked *